Hiroyuki Kobori Selected Research

olmesartan

1/2018	Effects of Olmesartan and Azilsartan on Albuminuria and the Intrarenal Renin-Angiotensin System.
10/2016	Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients.
3/2013	The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.
1/2013	Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats.
1/2013	Calcium channel blocker enhances beneficial effects of an angiotensin II AT1 receptor blocker against cerebrovascular-renal injury in type 2 diabetic mice.
5/2012	Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
3/2012	Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation.
3/2012	Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice.
3/2011	Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats.
11/2010	Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroyuki Kobori Research Topics

Disease

57	Hypertension (High Blood Pressure) 01/2019 - 03/2001
17	Albuminuria 01/2021 - 09/2008
17	Diabetic Nephropathies (Diabetic Nephropathy) 01/2017 - 05/2006
14	Proteinuria 01/2018 - 03/2005
12	Chronic Renal Insufficiency 01/2019 - 09/2008
11	Type 2 Diabetes Mellitus (MODY) 01/2019 - 12/2009
10	IGA Glomerulonephritis (IGA Nephropathy) 01/2018 - 05/2006
9	Fibrosis (Cirrhosis) 01/2020 - 09/2008
6	Inflammation (Inflammations) 06/2015 - 01/2008
6	Kidney Diseases (Kidney Disease) 10/2014 - 05/2006
5	Body Weight (Weight, Body) 01/2019 - 09/2008
4	Hypertrophy 01/2019 - 01/2008
4	Glomerulonephritis 06/2015 - 01/2010
4	Wounds and Injuries (Trauma) 01/2014 - 07/2005
4	Nephritis 09/2011 - 05/2008
3	Insulin Resistance 01/2018 - 11/2013
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2016 - 05/2010
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 06/2015 - 12/2009
3	Essential Hypertension 07/2014 - 09/2011
3	Vascular System Injuries 01/2014 - 04/2003
3	Obesity 04/2012 - 04/2010
2	Necrosis 01/2019 - 10/2012
2	Stroke (Strokes) 11/2018 - 06/2012
2	Glycosuria 06/2018 - 12/2015
2	Vascular Remodeling 01/2014 - 10/2011
2	Cognitive Dysfunction 01/2013 - 03/2011
2	Renal Hypertension 01/2012 - 06/2011
2	Sclerosis 03/2010 - 07/2005
1	Hypoxia (Hypoxemia) 01/2019
1	Nephrosclerosis 11/2018

Drug/Important Bio-Agent (IBA)

57	AngiotensinogenIBA 01/2021 - 03/2001
30	Angiotensin IIIBA 01/2021 - 03/2001
22	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2001
16	SodiumIBA 06/2018 - 03/2003
15	SaltsIBA 04/2015 - 01/2003
14	Messenger RNA (mRNA)IBA 01/2019 - 03/2001
13	ReninIBA 10/2014 - 02/2002
11	olmesartanIBA 01/2018 - 07/2004
9	Glucose (Dextrose)FDA LinkGeneric 06/2018 - 03/2005
9	AngiotensinsIBA 06/2013 - 01/2003
8	Angiotensin Receptor AntagonistsIBA 01/2018 - 06/2009
8	CreatinineIBA 10/2017 - 09/2008
8	Biomarkers (Surrogate Marker)IBA 12/2014 - 09/2008
8	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2013 - 10/2003
7	Angiotensin II Type 1 Receptor BlockersIBA 03/2013 - 01/2006
6	AlbuminsIBA 10/2017 - 09/2008
6	Immunoglobulin A (IgA)IBA 01/2011 - 05/2006
5	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 02/2013 - 02/2009
5	Hydralazine (Apresoline)FDA LinkGeneric 03/2012 - 03/2004
4	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 12/2015 - 01/2006
4	AldosteroneIBA 09/2014 - 03/2012
4	Eplerenone (Inspra)FDA LinkGeneric 03/2012 - 03/2010
3	DesminIBA 01/2019 - 11/2010
3	Valsartan (Vals)FDA Link 04/2016 - 01/2011
3	aliskiren FDA Link 01/2016 - 01/2012
3	Prorenin ReceptorIBA 03/2015 - 06/2012
3	Transforming Growth Factors (Transforming Growth Factor)IBA 10/2014 - 09/2009
3	Superoxides (Superoxide)IBA 01/2014 - 03/2004
3	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2014 - 01/2012
3	CytokinesIBA 01/2014 - 05/2012
3	Antihypertensive Agents (Antihypertensives)IBA 01/2013 - 05/2006
3	tempolIBA 01/2012 - 03/2004
3	Drinking WaterIBA 11/2010 - 07/2004
2	NPHS2 proteinIBA 01/2019 - 03/2010
2	nephrinIBA 01/2019 - 03/2010
2	Losartan (Cozaar)FDA LinkGeneric 01/2019 - 04/2011
2	Sodium-Glucose Transporter 2 InhibitorsIBA 06/2018 - 10/2017
2	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2018 - 06/2013
2	candesartanIBA 01/2018 - 11/2010
2	azilsartanIBA 01/2018 - 06/2017
2	Sodium-Glucose Transport ProteinsIBA 10/2017 - 12/2015
2	Renin InhibitorsIBA 01/2016 - 01/2006
2	Spironolactone (Aldactone)FDA LinkGeneric 12/2015 - 11/2013
2	Small Interfering RNA (siRNA)IBA 03/2015 - 06/2012
2	Insulin (Novolin)FDA Link 09/2014 - 10/2011
2	GlucocorticoidsIBA 11/2013 - 08/2010
2	Chymases (Chymase)IBA 02/2013 - 09/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2012 - 10/2010
2	CollagenIBA 01/2012 - 03/2011
2	Phosphotransferases (Kinase)IBA 10/2011 - 11/2010
2	salicylhydroxamic acid (SHAM)IBA 06/2011 - 01/2003
2	Purinergic P2 Receptors (ADP Receptor)IBA 06/2011 - 01/2008
2	N-Type Calcium Channels (N-Type Calcium Channel)IBA 05/2010 - 05/2006
2	ImmunosorbentsIBA 04/2010 - 12/2009
2	EnzymesIBA 04/2010 - 12/2009
2	Telmisartan (Micardis)FDA Link 03/2010 - 09/2008
2	Indicators and Reagents (Reagents)IBA 06/2009 - 01/2003
1	MelatoninIBA 01/2019
1	esaxerenoneIBA 01/2019
1	Fibronectins (Fibronectin)IBA 01/2019
1	SymportersIBA 06/2018
1	LipidsIBA 01/2018
1	Prednisolone (Predate)FDA LinkGeneric 01/2018
1	SteroidsIBA 01/2018

Therapy/Procedure

8	Therapeutics 01/2018 - 07/2005
2	Sympathectomy (Sympathectomies) 12/2015 - 03/2012
2	Sodium-Restricted Diet (Diet, Sodium Restricted) 03/2013 - 08/2011
2	Uterine Myomectomy 08/2009 - 07/2006
1	Chronotherapy 01/2019
1	Oral Administration 06/2018